Kyverna Therapeutics, Inc. ( KYTX) - Key Metrics
KYTX Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0 | -$0.63 | -$0.66 | -$0.67 |
| 2026Q1 | $0 | -$0.66 | -$0.69 | -$0.69 |
| 2025Q4 | $0 | -$0.80 | -$0.71 | -$0.71 |
| 2025Q3 | $0 | -$0.85 | -$1 | -$1.01 |
| 2025Q2 | $0 | -$0.97 | -$0.74 | -$0.74 |
KYTX Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -3.54 |
| 2026Q1 | 0% | -3.27 |
| 2025Q4 | 0% | -2.94 |
| 2025Q3 | 0% | -1.76 |
| 2025Q2 | 0% | -0.79 |
KYTX
Price: $8.13
52 week price:
Earnings Per Share: -3.21 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Market Capitalization: 553.5 million